Daily costs of prostaglandin analogues as monotherapy or in fixed combinations with timolol, in Denmark, Finland, Germany and Sweden

Anders Bergstr&ouml;m1, Fr&eacute;d&eacute;rique Maurel2, Claude Le Pen3, Emilie Lamure2, Michael Kent4, Isabelle Bardoulat2, Gilles Berdeaux5,61Lund Hospital, Lund, Sweden; 2IMS France, Puteaux, France; 3Universit&eacute; Paris-Dauphine, Paris, France; 4Alcon Inc, Fo...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Anders Bergstr&ouml;m, Fr&eacute;d&eacute;rique Maurel, Claude Le Pen, et al
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2009
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/f5902438af1044e689e13064f8fd2e91
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f5902438af1044e689e13064f8fd2e91
record_format	dspace
spelling	oai:doaj.org-article:f5902438af1044e689e13064f8fd2e912021-12-02T06:55:25ZDaily costs of prostaglandin analogues as monotherapy or in fixed combinations with timolol, in Denmark, Finland, Germany and Sweden1177-54671177-5483https://doaj.org/article/f5902438af1044e689e13064f8fd2e912009-08-01T00:00:00Zhttp://www.dovepress.com/daily-costs-of-prostaglandin-analogues-as-monotherapy-or-in-fixed-comb-a3453https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Anders Bergstr&ouml;m1, Fr&eacute;d&eacute;rique Maurel2, Claude Le Pen3, Emilie Lamure2, Michael Kent4, Isabelle Bardoulat2, Gilles Berdeaux5,61Lund Hospital, Lund, Sweden; 2IMS France, Puteaux, France; 3Universit&eacute; Paris-Dauphine, Paris, France; 4Alcon Inc, Fort Worth, Texas, USA; 5Alcon France SA, Rueil-Malmaison, France; 6Conservatoire National des Arts et M&eacute;tiers, Paris, FranceBackground: To compare the daily costs of 3 prostaglandin analogues (bimatoprost, latanoprost, travoprost), alone, and associated with timolol in 4 European countries (Denmark, Finland, Germany, and Sweden).Methods: Six glaucoma products were sampled by buying 5 bottles from 1 suburban pharmacy in each of the 4 countries. Drops were weighed by a single operator at 1 site according to standardized procedures. Residual drops were then counted. Unit bottle costs were estimated from tariff lists. Eye-drop weights were entered into a nested analysis of variance comprising drug, instillation day, country, the interaction, and a sample factor nested within the country factor. Effectiveness was represented by treatment failure rates estimated from a meta-analysis and a general practitioner survey.Results: Every drug bottle contained sufficient drops to treat 1 patient for 28/31 days. Drop-size heterogeneity between countries was observed for bimatoprost and bimatoprost/timolol. Mean travoprost and travoprost/timolol drop-sizes were the smallest, and drop-counts per bottle were the lowest for latanoprost, or latanoprost/timolol. In all 4 countries annual costs were least for travoprost and travoprost/timolol.Conclusions: On taking into account drug costs and effectiveness, travoprost and travoprost/timolol were cheaper and more effective than latanoprost and latanoprost/timolol and were cheaper than bimatoprost and bimatoprost/timolol.Keywords: prostaglandin analogue, economics, daily cost Anders Bergstr&ouml;mFr&eacute;d&eacute;rique MaurelClaude Le Penet alDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2009, Iss default, Pp 471-481 (2009)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Anders Bergstr&ouml;m Fr&eacute;d&eacute;rique Maurel Claude Le Pen et al Daily costs of prostaglandin analogues as monotherapy or in fixed combinations with timolol, in Denmark, Finland, Germany and Sweden
description	Anders Bergstr&ouml;m1, Fr&eacute;d&eacute;rique Maurel2, Claude Le Pen3, Emilie Lamure2, Michael Kent4, Isabelle Bardoulat2, Gilles Berdeaux5,61Lund Hospital, Lund, Sweden; 2IMS France, Puteaux, France; 3Universit&eacute; Paris-Dauphine, Paris, France; 4Alcon Inc, Fort Worth, Texas, USA; 5Alcon France SA, Rueil-Malmaison, France; 6Conservatoire National des Arts et M&eacute;tiers, Paris, FranceBackground: To compare the daily costs of 3 prostaglandin analogues (bimatoprost, latanoprost, travoprost), alone, and associated with timolol in 4 European countries (Denmark, Finland, Germany, and Sweden).Methods: Six glaucoma products were sampled by buying 5 bottles from 1 suburban pharmacy in each of the 4 countries. Drops were weighed by a single operator at 1 site according to standardized procedures. Residual drops were then counted. Unit bottle costs were estimated from tariff lists. Eye-drop weights were entered into a nested analysis of variance comprising drug, instillation day, country, the interaction, and a sample factor nested within the country factor. Effectiveness was represented by treatment failure rates estimated from a meta-analysis and a general practitioner survey.Results: Every drug bottle contained sufficient drops to treat 1 patient for 28/31 days. Drop-size heterogeneity between countries was observed for bimatoprost and bimatoprost/timolol. Mean travoprost and travoprost/timolol drop-sizes were the smallest, and drop-counts per bottle were the lowest for latanoprost, or latanoprost/timolol. In all 4 countries annual costs were least for travoprost and travoprost/timolol.Conclusions: On taking into account drug costs and effectiveness, travoprost and travoprost/timolol were cheaper and more effective than latanoprost and latanoprost/timolol and were cheaper than bimatoprost and bimatoprost/timolol.Keywords: prostaglandin analogue, economics, daily cost
format	article
author	Anders Bergstr&ouml;m Fr&eacute;d&eacute;rique Maurel Claude Le Pen et al
author_facet	Anders Bergstr&ouml;m Fr&eacute;d&eacute;rique Maurel Claude Le Pen et al
author_sort	Anders Bergstr&ouml;m
title	Daily costs of prostaglandin analogues as monotherapy or in fixed combinations with timolol, in Denmark, Finland, Germany and Sweden
title_short	Daily costs of prostaglandin analogues as monotherapy or in fixed combinations with timolol, in Denmark, Finland, Germany and Sweden
title_full	Daily costs of prostaglandin analogues as monotherapy or in fixed combinations with timolol, in Denmark, Finland, Germany and Sweden
title_fullStr	Daily costs of prostaglandin analogues as monotherapy or in fixed combinations with timolol, in Denmark, Finland, Germany and Sweden
title_full_unstemmed	Daily costs of prostaglandin analogues as monotherapy or in fixed combinations with timolol, in Denmark, Finland, Germany and Sweden
title_sort	daily costs of prostaglandin analogues as monotherapy or in fixed combinations with timolol, in denmark, finland, germany and sweden
publisher	Dove Medical Press
publishDate	2009
url	https://doaj.org/article/f5902438af1044e689e13064f8fd2e91
work_keys_str_mv	AT andersbergstrampoumlm dailycostsofprostaglandinanaloguesasmonotherapyorinfixedcombinationswithtimololindenmarkfinlandgermanyandsweden AT frampeacutedampeacuteriquemaurel dailycostsofprostaglandinanaloguesasmonotherapyorinfixedcombinationswithtimololindenmarkfinlandgermanyandsweden AT claudelepen dailycostsofprostaglandinanaloguesasmonotherapyorinfixedcombinationswithtimololindenmarkfinlandgermanyandsweden AT etal dailycostsofprostaglandinanaloguesasmonotherapyorinfixedcombinationswithtimololindenmarkfinlandgermanyandsweden
_version_	1718399729960747008

Daily costs of prostaglandin analogues as monotherapy or in fixed combinations with timolol, in Denmark, Finland, Germany and Sweden

Ejemplares similares